Hematoporphyrin derivative and anthracyclines mutually inhibit cellular uptake and toxicity

Area of Science:

• Oncology
• Biochemistry
• Pharmacology

Background:

• Hematoporphyrin derivative (HpD) is a photosensitizer used in cancer photoirradiation therapy.
• Combining photoirradiation with chemotherapy may offer synergistic anti-cancer effects.
• Understanding drug interactions is crucial for optimizing combination cancer treatments.

Purpose of the Study:

• To investigate the interaction between Hematoporphyrin derivative (HpD) and various cytotoxic chemotherapy drugs.
• To determine the impact of HpD on the cellular uptake and toxicity of drugs like daunorubicin (DR), adriamycin (AD), and mitozantrone (MI).
• To assess potential interactions with cis-platinum (CP) and 5-fluorouracil (FU).

Main Methods:

• Cultured cells were incubated with HpD and cytotoxic drugs, either simultaneously or sequentially.
• Cellular uptake of DR, AD, and HpD was quantified using fluorescence measurements.
• Cytotoxicity was assessed by light-induced cell kill (for HpD) and loss of proliferative potential (for cytotoxic drugs).

Main Results:

• Co-incubation with HpD significantly reduced the cytotoxicity of DR (30-fold), AD (12-fold), and MI (6-fold).
• HpD reduced its own fluorescence and photosensitization when co-incubated with AD, suggesting an extracellular interaction.
• Sequential incubation with HpD and AD did not reduce cytotoxicity, indicating the interaction is primarily extracellular.
• Cis-platinum (CP) and 5-fluorouracil (FU) showed no interaction with HpD.

Conclusions:

• Hematoporphyrin derivative (HpD) interacts with anthracyclines (like AD and DR) extracellularly, reducing their availability for cellular uptake and subsequent cytotoxicity.
• Combination therapy protocols involving HpD and anthracyclines require adjustments to account for this antagonistic interaction.
• HpD does not interact with platinum-based or antimetabolite chemotherapy drugs (CP, FU).